Postpartum hemorrhage (PPH) is the leading cause of maternal death worldwide. The World Maternal Antifibrinolytic trial showed that antifibrinolytic tranexamic acid (TXA) reduces PPH deaths. Maternal anemia increases the risk of PPH. The World Maternal Antifibrinolytic-2 trial is now assessing whether TXA can prevent PPH in women with anemia. Low red blood cell (RBC) counts promote fibrinolysis by altering fibrin structure and plasminogen activation. We explored interactions between RBCs and TXA in inhibiting fibrinolysis. We used global fibrinolytic assays (ball sedimentation and viscoelasticity) to monitor the lysis of fibrin containing plasminogen and tissue-type plasminogen activator. We applied a fluorogenic kinetic assay to measure plasmin generation in fibrin clots and scanning electron microscopy to study fibrin structure. According to parallel-line bioassay analysis of the fibrin lysis-time data, the antifibrinolytic potency of 4-128 μM TXA was increased in the presence of 10% to 40% (v/v) RBCs. Global fibrinolysis assays showed that the joint effect of RBCs and TXA was about 15% larger than the sum of their individual effects in the inhibition of fibrinolysis. In plasminogen activation, TXA added the same increment of inhibition to the effect of RBCs at any cell count in the fibrin clot. Regarding fibrin structure, TXA thickened fibrin fibers, which impaired plasminogen activation, whereas RBCs promoted fine fibers that were more resistant to plasmin. The antifibrinolytic potency of TXA is enhanced in fibrin formed in the presence of RBCs through inhibition of plasminogen activation and fibrin lysis, which correlates with modifications of fibrin structures.
Surface Plasmon Resonance (SPR) is a popular method for studying biomolecular interactions without labels. One common challenge with analyzing SPR signals is that sometimes the dissociation phase does not return to the baseline quickly enough. This study aimed to create a tool to improve the accuracy of the traditional Langmuir 1:1 binding model in these tough cases, specifically for the interaction between plasminogen and fibrin. Our approach is based on the idea that there is a secondary binding component that appears to be irreversible within the measurement time. This secondary binding is mixed with the primary binding in the overall SPR signal. We developed a new mathematical method that separates the overall SPR data into three types of ligand–analyte complexes: a primary reversible complex, a secondary irreversible complex, and their combination. Using this method to analyse plasminogen binding to fibrin, we achieved improved results. Compared with the simpler model, the mean adjusted coefficient of determination increased from 0.59 to 0.75, and the normalized root mean square error decreased from 1.9% to 1.4%. The binding parameters we obtained using our model closely matched values from other techniques, supporting the effectiveness of our approach.